On August 7, 2024, Novo Nordisk released its financial report for the first half of 2024, with operating revenue of 133.4 billion Danish kroner (DKK), equivalent to 19.5 billion US dollars, a year-on-year increase of 24%; Net profit was 45.5 billion Danish kroner, equivalent to 6.65 billion US dollars, a year-on-year increase of 16%. Among them, the sales revenue of semaglutide is nearly 13 billion US dollars, just one step away from the throne of the drug king.
In addition, Novo Nordisk has revealed that its Phase III OASIS 4 study on weight loss with oral semaglutide Rybelsus (25mg) has been successfully completed. From the perspective of the domestic market, there are currently four GLP-1 receptor agonists approved for weight loss indications, and multiple GLP-1 RA products are in the stage of market application or clinical phase III for weight loss indications, with a focus on the relevant developments in biotechnology and other concepts.
Related ETFs: Biotechnology ETF (516500), Hang Seng Pharmaceutical ETF (159892)